United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals

Zoom Video

Here's why you should catch the rising wave on these three coronavirus stocks.

Buy Alert: These 3 Coronavirus Stocks Are Heading Higher

Abbott Labs

Their coronavirus programs are only part of the attraction for these stocks.

3 Top Coronavirus Stocks to Buy in October

Pfizer Reports Data, And Other News: The Good, Bad And Ugly Of Biopharma

Most drug stocks are very expensive, but PFE stock is a Covid-19 vaccine play that is still selling at a reasonable price. The post Pfizer Is a Value Play in the Covid-19 Frenzy appeared first on InvestorPlace.

Pfizer Is a Value Play in the Covid-19 Frenzy

NEU-ISENBURG, Germany & FRANKFURT, Germany & NEW YORK--(BUSINESS WIRE)--The German Breast Group (GBG) and Pfizer Inc. (NYSE: PFE) today announced that the collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (eBC) who have residual invasive disease after completing neoadjuvant chemotherapy. No unexpected safety si

PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint

OPKO Health

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to

Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency

Moderna

The coronavirus vaccine race has two likely winners that have surged ahead in a crowded field, according to an SVB Leerink analyst. Pfizer, Moderna In The Lead: It now appears that Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), along with its German partner BioNTech SE – ADR (NASDAQ: BNTX), have a two month or more advantage over their nearest rivals among coronavirus vaccine developers, SVB Leerink analyst Geoffrey Porges said in a Wednesday note.

Moderna, Pfizer Have 2-Month Lead Over Coronavirus Vaccine Competitors: Analyst

Gilead Sciences

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

West Pharmaceutical Services

As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on InvestorPlace.

7 Biotech Stocks To Buy For Profit From The Vaccine Crunch

AstraZeneca

Invesco DWA SmallCap Momentum ETF

Inovio Pharmaceuticals

iShares Russell 2000 Growth ETF

iShares Morningstar Small-Cap Growth ETF

Johnson & Johnson

Merck

Vanguard Small-Cap Growth

Vanguard Russell 2000 Growth 

Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.

Here's Why Small-Cap ETFs Are Hitting New Highs

BioNTech SE

Pfizer (PFE) and partner BioNTech start rolling review of their coronavirus vaccine candidate, BNT162b2, in Europe.

Pfizer, BioNTech Begin EU Rolling Filing of Coronavirus Vaccine

Our indicative theme of Coronavirus Vaccine stocks – which includes a diverse set of U.S. based pharma and biotech stocks that are working on Covid-19 vaccines – is up by about 730% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 4% over the same.

Moderna, Pfizer, Johnson & Johnson: How Are Covid Vaccine Stocks Doing?

European health regulator launches a “rolling review” of the coronavirus vaccine being developed by Pfizer and BioNTech, as it did for the competing Oxford-AstraZeneca vaccine.

How the EU will speed up approval of eventual COVID-19 vaccine

Sangamo Therapeutics

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with modera

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment

Exact Sciences

MADISON, Wis. and NEW YORK, Oct. 7, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Pfizer Inc. (NYSE: PFE) today announced an extension and amendment of their agreement to promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal...

Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement

JPMorgan Chase & Co

Coca-Cola

Walmart

Blue-chip stocks should look especially attractive to investors now that uncertainty reigns. Read on to learn which are strongest.

5 Blue-chip Stocks to Buy on a Discount to Fortify Portfolios

That's a slight delay from the companies' best-case scenarios.

Expect Pfizer/BioNTech and Moderna Coronavirus Vaccine Data Readouts in November-December, U.S. Vaccine Program Head Says

Pharmaceutical companies developing COVID-19 vaccines should wait two months after late-stage studies conclude to submit an application for an emergency use authorization to the Food and Drug Administration, the regulator said Tuesday.

FDA to require 2-month follow-up period for COVID-19 vaccines before authorization

SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.

SpringWorks Inks Deal With Pfizer for Nirogacestat Combo

Pfizer and BioNTech will share the data from their phase 3 clinical trial with the European Medicines Agency as it comes in.

EU Regulators Undertake Rolling Review of Another Coronavirus Vaccine Candidate

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) cemented their lead in the coronavirus vaccine race by beginning the rolling submission of the regulatory application in Europe. What Happened: The U.S.-German collaborators announced Tuesday they have initiated a rolling submission with the European Medicines Agency, or EMA, for BNT16b2, the lead candidate from their joint vaccine program.

Pfizer-BioNTech Establish Lead In Coronavirus Vaccine Race, Kickstarts Regulatory Filing Process In Europe

BioNTech and partner Pfizer announced the start of a rolling submission process for the approval of their Covid-19 vaccine candidate in Europe. The post Pfizer, BioNTech Start Approval Process For Covid-19 Vaccine Candidate In Europe appeared first on Investor's Business Daily.

Pfizer, BioNTech Start Approval Process For Covid-19 Vaccine Candidate In Europe

Pfizer Inc. PFE, +1.01% and BioNTech SE BNTX, +9.49% said the European Medicines Agency has decided to review data from their COVID-19 vaccine candidate on a rolling basis and has already started to evaluate data from pre-clinical trials. The decision "follows the encouraging preliminary results from pre-clinical and early clinical studies in adults, which suggest that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2," the companies said in a joint statement.

Pfizer and BioNTech says European Medicines Agency to review data from COVID-19 vaccine trial on rolling basis

The three companies are accused of using a fluorescent protein in their research without paying royalties for it.

Pfizer, BioNTech, and Regeneron Hit With Patent Lawsuits Over COVID-19 Drugs and Vaccines

Cisco Systems

CVS Health

H&R Block

NetApp

Northern Trust

Given the uncertainty surrounding the election and the economy, investors may want to look at these 7 value stocks to beat out volatility. The post 7 Cheap Stocks to Buy Today For A Defensive Bargain appeared first on InvestorPlace.

7 Cheap Stocks to Buy Today For A Defensive Bargain

The partners may not complete enrollment before Moderna, but they do have a lead in one critical enrollment measurement.

News for Pfizer Stock (PFE)